Patents by Inventor David LIBERG

David LIBERG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-IL1RAP antibody
    Publication number: 20230108007
    Abstract: The present invention relates to an antibody or antigen-binding fragment thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibody, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibody or antigen-binding fragment. Further, it relates to a composition comprising said antibody or antigen-binding fragment, said polynucleotide, said vector and/or said host cell.
    Type: Application
    Filed: June 9, 2022
    Publication date: April 6, 2023
    Applicant: Cantargia AB
    Inventors: David Liberg, Camilla Rydberg Millrud, Gabriel Svensson Birkedal, Sara Rattik, Kjell Sjöström, Karin von Wachenfeldt, Caitríona Grönberg
  • Anti-IL1RAP antibody
    Patent number: 11479610
    Abstract: The present invention relates to an antibody or antigen-binding fragment thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibody, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibody or antigen-binding fragment. Further, it relates to a composition comprising said antibody or antigen-binding fragment, said polynucleotide, said vector and/or said host cell.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: October 25, 2022
    Assignee: Cantargia AB
    Inventors: David Liberg, Camilla Rydberg Millrud, Gabriel Svensson Birkedal, Sara Rattik, Kjell Sjöström, Karin von Wachenfeldt, Caitríona Grönberg
  • Anti-IL1RAP Antibody Compositions
    Publication number: 20220267454
    Abstract: The present invention relates to antibody compositions directed to Interleukin 1 Receptor Accessory Protein (IL1RAP) and their use in the treatment and diagnosis of diseases associated with IL1RAP, such as inflammatory, autoimmune, autoinflammatory and neoplastic disorders.
    Type: Application
    Filed: August 15, 2019
    Publication date: August 25, 2022
    Applicant: Cantargia AB
    Inventors: Göran Forsberg, David Liberg, Kjell Sjöström, Karin von Wachenfeldt
  • Anti-IL1RAP antibody
    Publication number: 20220242950
    Abstract: The present invention relates to an antibody or antigen-binding fragment thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibody, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibody or antigen-binding fragment. Further, it relates to a composition comprising said antibody or antigen-binding fragment, said polynucleotide, said vector and/or said host cell.
    Type: Application
    Filed: December 22, 2021
    Publication date: August 4, 2022
    Applicant: Cantargia AB
    Inventors: David Liberg, Camilla Rydberg Millrud, Gabriel Svensson Birkedal, Sara Rattik, Kjell Sjöström, Karin von Wachenfeldt, Caitríona Grönberg
  • Quinoline carboxamides for use in the treatment of multiple myeloma
    Patent number: 10314836
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: June 11, 2019
    Assignee: Active Biotech AB
    Inventors: David Liberg, Anders Olsson, Dmitry Gabrilovich, Yuliya Nefedova
  • N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors
    Patent number: 10125125
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between SI 00A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: November 13, 2018
    Assignee: Active Biotech AB
    Inventors: Ingela Fritzson, David Liberg, Stephen East, Colin Mackinnon, Natacha Prevost
  • QUINOLINE CARBOXAMIDES FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA
    Publication number: 20180228794
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Application
    Filed: April 6, 2018
    Publication date: August 16, 2018
    Inventors: David LIBERG, Anders OLSSON, Dmitry GABRILOVICH, Yuliya NEFEDOVA
  • N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS
    Publication number: 20180155330
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between SI 00A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: December 8, 2017
    Publication date: June 7, 2018
    Inventors: Ingela FRITZSON, David LIBERG, Stephen EAST, Colin MACKINNON, Natacha PREVOST
  • Quinoline carboxamides for use in the treatment of multiple myeloma
    Patent number: 9956212
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: May 1, 2018
    Assignee: Active Biotech AB
    Inventors: David Liberg, Anders Olsson, Dmitry Gabrilovich, Yuliya Nefedova
  • N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors
    Patent number: 9873687
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: January 23, 2018
    Assignee: Active Biotech AB
    Inventors: Ingela Fritzson, David Liberg, Stephen East, Colin Mackinnon, Natacha Prevost
  • QUINOLINE CARBOXAMIDES FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA
    Publication number: 20170273967
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Application
    Filed: September 18, 2015
    Publication date: September 28, 2017
    Inventors: David LIBERG, Anders OLSSON, Dmitry GABRILOVICH, Yuliya NEFEDOVA
  • Compounds useful as S100-inhibitors
    Patent number: 9771372
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: September 26, 2017
    Assignee: Active Biotech AB
    Inventors: Ulf Wellmar, David Liberg, Maria Ekblad, Marie Bainbridge, Stephen East, Jonathan Hargrave, Natacha Prevost
  • NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS
    Publication number: 20170204098
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: May 22, 2015
    Publication date: July 20, 2017
    Inventors: Ulf WELLMAR, David LIBERG, Maria EKBLAD, Marie BAINBRIDGE, Stephen EAST, Jonathan HARGRAVE, Natacha PREVOST
  • N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS
    Publication number: 20160115158
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: May 14, 2014
    Publication date: April 28, 2016
    Inventors: Ingela FRITZSON, David LIBERG, Stephen EAST, Colin MACKINNON, Natacha PREVOST